Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin,
epirubicin hydrochloride, and capecitabine, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving
gemcitabine hydrochloride, with or without cisplatin, epirubicin hydrochloride, and
capecitabine before surgery may make the tumor smaller and reduce the amount of normal tissue
that needs to be removed. Giving these drugs after surgery may kill any tumor cells that
remain after surgery.
PURPOSE: This randomized phase II/III trial is studying how well gemcitabine hydrochloride,
with or without cisplatin, epirubicin hydrochloride, and capecitabine, works when given
before and/or after surgery in treating patients with stage I or stage II pancreatic cancer
that can be removed by surgery.